MME and hydrops fetalis: Recently, the combination of sacubitril, an inhibitor of the neutral endopeptidase (NEP, neprilysin) which protects natriuretic peptides from degradation, with an angiotensin AT1 receptor antagonist (valsartan) has been introduced for the treatment of chronic heart failure (HF), especially in patients with reduced ejection fraction.